Chiesi Global Rare Diseases Announces Health Canada Approval of Elfabrio® (pegunigalsidase alfa) for Fabry Disease
Approval of Elfabrio® provides an additional treatment option for those living with Fabry disease PARMA, Italy and WOODBRIDGE, Ontario, Dec. 16, 2025 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver in
(Financial Post, 2025-12-16T13:33:32Z)